| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 8.2B | +19% |
| Gross Profit | 5.1B | - |
| Cost Of Revenue | 3.1B | +72% |
| Operating Income | 1.3B | -37% |
| Operating Expenses | 3.8B | - |
| Net Income | 767MM | -56% |
| R&D | 1.5B | +42% |
| G&A | 2.3B | +68% |
| Amortization | 1.1B | +62% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Amgen (AMGN) concluded the recent trading session at $264.07, signifying a -0.59% move from its prior day's close.
Amgen's shares have come under pressure this year, making it a compelling bargain buy.
Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.
Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT.
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In the most recent trading session, Amgen (AMGN) closed at $270, indicating a +1.33% shift from the previous trading day.
Amgen's stock isn't expensive, but the business does face some challenges, which could have investors thinking twice.
GLP-1 medications will likely expand beyond their current uses for diabetes or weight loss, according to money managers at Tema
In this article, we discuss 11 best biotech ETFs to buy. If you want to skip our discussion on the biotech industry, head over to 5 Best Biotech ETFs To Buy. The new era in biotech is defined by the convergence of biology, data, and artificial intelligence. According to The Journal of mHealth, the focus […]
It’s been a volatile start to the second quarter for many sectors. However, investors continue to seek out undervalued biotech stocks for robust returns over the long term. Plenty of options exist in various niches within the biotech sector. That said, investor focus remains on key sectors, including weight-loss drugs, Parkinson’s treatments and drugs aimed at Alzheimer’s. It’s worth pointing out that biotech stocks are among some of the higher-risk options in the market. These companies’ massiv